CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Robert L. Ferris(University of Pittsburgh), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Tamara Rordorf(Institut Gustave Roussy), Naomi Kiyota(Kobe University Hospital), Nabil F. Saba(Emory University), Lisa Licitra(University of Milan), Lara Carmen Iglesias Docampo(Institut Gustave Roussy), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Manish Monga(Institut Gustave Roussy), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Li Li(Sichuan University), Stefan Kasper(Essen University Hospital), Caroline Even(Institut Gustave Roussy), J. Guigay(Centre Antoine Lacassagne)
Cited by 96
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k